Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07572123CT.gov Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07275216CT.gov Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | — | Recruiting | — | — | — |
NCT06563245CT.gov Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | — | Recruiting | — | — | — |
NCT06563778CT.gov Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. | — | Not Yet Recruiting | — | — | — |
NCT06393361CT.gov Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. | — | Recruiting | — | — | — |
NCT05711628CT.gov A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT07171827CT.gov Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT05404945CT.gov Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | — | Active Not Recruiting | — | — | — |
NCT05039073CT.gov Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | — | Recruiting | — | — | — |
NCT05243693CT.gov Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma | — | Unknown | — | — | — |
Show 17 more trialsShow fewer
NCT04138875CT.gov A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) | — | Withdrawn | — | — | — |
NCT04561206CT.gov Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT04254107CT.gov A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | — | Terminated | — | — | — |
NCT03652441CT.gov Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03907488CT.gov Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03712202CT.gov Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03729609CT.gov Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma" | — | Completed | — | — | — |
NCT03205891CT.gov Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | — | Withdrawn | — | — | — |
NCT03527628CT.gov OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | — | Unknown | — | — | — |
NCT03233347CT.gov Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03057795CT.gov Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02661503CT.gov HD21 for Advanced Stages | — | Unknown | — | — | — |
NCT02758717CT.gov Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02166463CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02243436CT.gov Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01896999CT.gov Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01771107CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brentuximab Vedotin (this asset) | National Cancer Institute (NCI) | P3 | BB · 66 |
| Dacarbazine | City of Hope Medical Center | P3 | BB |
| Vinblastine | University of Washington | P2 | BB |
| Etoposide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Adriamycin | Michael Spinner, MD | P3 | BB |
| Tislelizumab | Children's Cancer Group, China | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Gls-010 | Guangzhou Gloria Biosciences Co., Ltd. | P3 | BB |
| Carboplatin | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Classic Hodgkin Lymphoma cohort
Other indications for Brentuximab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Anaplastic Large Cell Lymphoma | — | P3 | BBB · 72 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brentuximab Vedotin in Classic Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brentuximab-vedotin-classic-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →